FGF21 and metabolic dysfunction-associated steatotic liver disease: Circulating FGF-21 was higher in patients with NAFLD compared to controls (SMD: 0.61; 95% CI: 0.44, 0.77; P < 0.00001) (Table 2; Fig. 3).